2,3,4′,5‐TETRAHYDROXYSTILBENE‐2‐O‐β‐d‐GLUCOSIDE SUPPRESSES MATRIX METALLOPROTEINASE EXPRESSION AND INFLAMMATION IN ATHEROSCLEROTIC RATS
Authors:
- 31 October 2007
- journal article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 35 (3) , 310-316
Abstract
SUMMARY: In coronary artery disease, the typical atheromatous plaque consists of a lipid core containing various inflammatory cells and a fibrous cap composed mostly of extracellular matrix. Both matrix metalloproteinases (MMPs) and inflammation are involved in the initiation of atherosclerotic plaques and plaque instability. 2,3,4¢,5‐Tetrahydroxystilbene‐2‐O‐b‐d‐glucoside (TSG) reduces the blood lipid content and prevents the atherosclerotic process, but the mechanism of action of TSG is unclear. The purpose of the present study was to test whether TSG can suppress MMP activation and inflammation in atherosclerotic rats. Sixty male Sprague‐Dawley rats were randomly divided into six groups. Atherosclerosis was induced by feeding rats a hyperlipidaemic diet; TSG (120, 60 or 30 mg/kg per day) was administered by oral gavage. After 12 weeks of treatment, rats were killed (ethyl carbamate 1200 mg/kg) and serum lipids, C‐reactive protein (CRP), interleukin (IL)‐6 and tumour necrosis factor (TNF)‐a were measured. Haematoxylin–eosin (H&E) staining was used to examine histopathological changes in the aorta. The mRNA and protein expression of MMPs were assayed by reverse transcription–polymerase chain reaction, immunohistochemistry and western blotting. Simvastatin (2 mg/kg per day) was administered as a positive control, whereas the vehicle (0.9% NaCl) group served as the untreated control. In the present study, TSG significantly and dose‐dependently attenuated the hyperlipidaemic diet‐induced alterations in serum lipid profile and increases in CRP, IL‐6 and TNF‐a levels. In addition, TSG normalized the structure of the aortic wall and suppressed the expression of MMP‐2 and MMP‐9 at both the mRNA and protein level in the rat aortic wall. In summary, TSG suppresses the expression of MMP‐2 and MMP‐9 and inhibits inflammation in the diet‐induced atherosclerotic rats.Keywords
This publication has 39 references indexed in Scilit:
- Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive ProteinJACC, 2007
- Inhibition of sphingosine-1-phosphate- and vascular endothelial growth factor-induced endothelial cell chemotaxis by red grape skin polyphenols correlates with a decrease in early platelet-activating factor synthesisFree Radical Biology and Medicine, 2006
- C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: Inhibitory effect of fluvastatinLife Sciences, 2006
- Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic MechanismsNature Reviews Drug Discovery, 2005
- Inflammation as a therapeutic target: a unique role for abciximabAmerican Heart Journal, 2003
- Inflammation in atherosclerosisNature, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosisExpert Opinion on Investigational Drugs, 2000
- Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.Journal of Clinical Investigation, 1994
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993